REGEN-COV

Important Information About REGEN-COV

Due to the high frequency of the Omicron variant, REGEN-COV (casirivimab and imdevimab) is not currently authorized in any U.S. region. Therefore, REGEN-COV may not be administered for treatment or post-exposure prevention of COVID-19 under the Emergency Use Authorization until further notice by the FDA.

REGEN-COV FDA EUA Resources

• Letter of Authorization
• Fact Sheet for Health Care Providers
• FDA Frequently Asked Question on the EUA for REGEN-COV

Distribution Table (Archive)

Self Life Extension

Product Resources